Breast CancerPhase 1LCCC1820NCT04142554
Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer
A Phase 1 study testing Parsaclisib in people with Breast Cancer and Breast Neoplasms, run by UNC Lineberger Comprehensive Cancer Center.
Trial summary
The purpose of this research study is to find the lowest dose of the cancer drug parsaclisib that has an effect on the type of breast cancer a participant has. Researchers are looking at how Parsaclisib affects the immune system. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Breast Cancer, Breast Neoplasms, Triple Negative Breast Cancer
- What is being tested?
- Parsaclisib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- 1 Jun 2020to 7 Sep 2020
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Is able to understand and give written informed consent for removal of at least 2 cores of tissue via a pre-treatment research biopsy. Is able to understand and give written informed consent for either collection of leftover tissue at time of surgery and via an end of treatment (EOT) research biopsy).
- Is ≥ 18 years of age.
- Has histologically confirmed newly diagnosed Stage I-IIIC invasive breast cancer that is triple negative (ER/PR <1%, HER2 negative) or HER2-positive, and meets the criteria listed below:
- HER 2 positive or overexpressed HER2 confirmed by immunohistochemistry (IHC), and florescence in situ hybridization (ISH) according to the 2018 ASCO-CAP guideline: i. IHC score of 3+ without ISH HER2/CEP17 OR ii. ISH HER2/CEP17 amplified with ratio higher than 2.0 OR if reported average HER2 copy number ≥ 6 signals/cell b. Scheduled for lumpectomy, mastectomy or neoadjuvant chemotherapy as first treatment for cancer c. No prior or current therapy for breast cancer d. Amenable to a baseline research breast biopsy e. Amenable to a post-therapy research biopsy (for patients going on to neoadjuvant chemotherapy and not straight to surgery). For patients going directly to surgery, post-therapy biopsy will be obtained at the time of surgery.
- Must have sufficient time to receive at least 7 consecutive days of parsaclisib therapy prior to definitive surgery or initiation of chemotherapy..
- Has an ECOG performance status ≤ 1.
Show all 22Show fewer
- Is able to swallow and retain oral medication.
- Demonstrates adequate organ function as defined below; all screening labs to be obtained within 72 hr of initiating study treatment.
- Hemoglobin (Hgb) - ≥ 10.0 g/dL
- Absolute Neutrophil Count (ANC) - ≥ 1.5 × 109/L
- Absolute Lymphocyte Count (ALC) - >500 cells/μL
- Platelets - ≥ 100 × 109/L
- Creatinine - ≤1.5 × ULN OR Calculated creatinine clearance - ≥ 60 mL/min for subject with creatinine levels > 1.5 × ULN (creatinine should be calculated per institutional standard)
- Bilirubin - ≤ 1.5 × ULN or direct bilirubin ≤ ULN for subject with total bilirubin >1.5 × ULN
- Aspartate aminotransferase (AST) - ≤ 2.5 × ULN
- Alanine aminotransferase (ALT) - ≤ 2.5 × ULN
- Albumin - ≥2.5 g/dL
- International Normalized Ratio (INR) or Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) - ≤ 1.5 × ULN unless subject is receiving anticoagulant therapy as long as PT and PTT is within therapeutic range of intended use of anticoagulants
- As determined by the enrolling physician or protocol designee, the subject is able to understand and comply with study procedures.
- For female subjects of childbearing potential: has a negative serum pregnancy test at screening within 72 hours of receiving study treatment. In addition, female subjects must either:
- Agree to the use of an approved method of contraception (i.e., two adequate barrier methods throughout the study starting with the screening visit) and to continue its use for the duration of the study treatment through 30 days after the last dose of parsaclisib if a female subject of child-bearing potential, or
- Has documented inability to become pregnant (e.g., hysterectomy, bilateral tubal ligation or oophorectomy, or post-menopausal as defined as total cessation of menses for 2 years). Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure otherwise the subject must be willing to use 2 adequate barrier methods throughout the study.
Who cannot join
- Prior history of another known malignancy other than breast cancer within the previous 2 years with the exception of adequately treated basal cell carcinoma or cervical intraepithelial neoplasia, cervical carcinoma in situ or melanoma in situ.
- Is pregnant or lactating.
- Has a concomitant medical condition that precludes adequate study treatment compliance or assessment, such as bleeding disorders or any other medical condition that would increase risks of additional core biopsy for biomarkers.
- Use of any potent CYP3A4 inhibitors or inducers (e.g., grapefruit or grapefruit juice) within 14 days or 5 half-lives (whichever is longer) before the first dose of parsaclisib.
- Has allergy to inactive components of the study medication.
- History of autoimmune disease or irritable bowel syndrome (IBS), or active colitis.
Show all 12Show fewer
- Inability to take oral medications (e.g., impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of oral medications such as ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
- Is participating in another therapeutic clinical trial or has received another investigational agent within 30 days prior to informed consent.
- Known Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection which is allowed).
- Has acute or currently active/requiring anti-viral therapy, hepatic or biliary disease (with the exception of subjects with Gilbert's syndrome, asymptomatic gallstones, or stable chronic liver disease per investigator assessment).
- Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
- Medical history of a disease that requires ongoing steroid therapy for >14 days.
About this study
Official title: Window of Opportunity Study of Parsaclisib in Subjects With Newly Diagnosed Stage I-IIIC Triple-Negative or HER2-Positive Breast Cancer
The purpose of this research study is to find the lowest dose of the cancer drug parsaclisib that has an effect on the type of breast cancer a participant has. Researchers are looking at how Parsaclisib affects the immune system. They want to learn whether and how it helps the immune system to find cancer cells to fight them.
Parsaclisib is an oral drug that limits the effects of a protein called phosphatidylinositol 3-kinase δ (PI3K). By limiting P13K, parsaclisib can block certain cells that prevent the immune cells from working. As a result, it may help the body's immune system to fight tumors. Parsaclisib is being studied in several clinical trials to treat different types of cancers. Parsaclisib has not yet been approved by FDA for the treatment of cancer.
Read more
Studies have shown that a good way to find out how cancer acts when exposed to anti-cancer drugs is through a pre-operative window study. In this type of study, tissue and blood are collected before treatment. Then subjects receive a study drug for a few weeks before surgery. Blood is drawn during the course of treatment, and leftover tissue is collected during surgery. Comparing the tissue and blood before and after treatment shows the effects the study drug may have had on the tumor.
Research shows that cancers differ when you look at the DNA and RNA (genetic codes) that are inside a cancer cell. DNA and RNA carry genetic information that can determine traits in humans (such as eye color, height, reaction to treatment, etc.), as well as the traits of cancer cells. Depending on the genetic profile (particularly DNA and RNA) of the cancer, it may respond differently to parsaclisib. In this study, the investigators will look at the genetic profile of a participant's tumor by studying tissue and blood samples collected before and after receiving treatment.
Read the detailed description
Surgery and Treatment:
Subjects must consent to having tissue collected for research purposes during a pre-treatment research biopsy, and scheduled surgery or end of treatment research biopsy prior to study entry. Prior to their scheduled standard of care surgery or research biopsy, subjects (n = 5 per dosing cohort) will be given oral doses of parsaclisib (10, 3.0 or 1.0 mg) once daily over 14 consecutive days. Cohorts will be enrolled sequentially by dose, where the cohort with the highest dose will be enrolled first and then the next cohort with the next highest dose will be enrolled after the enrollment of the prior cohort completes.
At each dose level it will be determined whether either a 50% increase in the intratumoral CD8+ T cells/regulatory T- cell ratio or a 50% decrease in the intratumoral percentage of regulatory T cells is observed in at least 3 subjects out of 5 at that dose level. If this criterion is met, enrollment in the next highest dose level will commence. This procedure will be repeated until either this criterion is met at the lowest dose level, or when the criterion is not satisfied in a particular dose level. In the latter case, the next highest dose level will be chosen as the "minimum effective dose". In the former case, the lowest dose level will be chosen as the minimum effective dose. The doses being administered are lower than the therapeutic dose levels of parsaclisib (i.e., 20 to 30 mg once daily) recommended for subjects with lymphoma. If the criterion is not met in the first (highest) dose level, then the investigators assume the minimum effective dose is the therapeutic dose of parsaclisib (20 mg once daily) and the study will be terminated.
Blood samples will be collected prior to parsaclisib treatment for research purposes. Subjects will undergo their standard of care surgical procedure or research biopsy within 72 hours (preferably within 24 hours) of completing drug treatment. Tissue and blood samples will be collected for correlative studies during surgery or during a research biopsy procedure. Subjects who have at least 7 days of parsaclisib treatment will be considered evaluable and may have tissue collected even if they have not completed the entire 14 day treatment regimen.
Duration of Follow Up:
Subjects will be followed post-operatively as per routine standard of care. Contraceptive use should continue for 93 days after the last dose of study drug administration. Subjects removed from study treatment for unacceptable adverse events will be followed until resolution or stabilization of the adverse event. Monitoring for AEs should continue for at least 30 days after the last dose of parsaclisib is administered. AEs related to therapy will then be followed until resolution to grade ≤1, or until the condition has stabilized with no further change expected.
- Conditions
- Breast Cancer, Breast Neoplasms, Triple Negative Breast Cancer, HER2-positive Breast Cancer
- Being tested
- Parsaclisib
- Keywords
- breast, triple negative, HER2-positive, parsaclisib
- Medical subject headings
- Breast Neoplasms, Triple Negative Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ParsaclisibDrug
Parsaclisib tablets (1.0, 2.5 or 5 mg) are administered orally daily for up to 14 days
| Study group | Role | What they receive |
|---|---|---|
| Single Arm: Parsaclisib ( Dose De-Escalation ) | Experimental | Prior to their scheduled standard of care surgery or research biopsy, subjects (n = 5 per dosing cohort) will be given oral doses of parsaclisib (10, 3.0 or 1.0 mg) once daily over 14 consecutive days. Receives: Drug: Parsaclisib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Minimum effective dose of parsaclisib
To determine the minimum dose of parsaclisib, administered once daily for 14 consecutive days, needed in subjects with triple-negative or human epidermal growth factor receptor 2 (HER2) positive breast cancer to result in either a 50% increase in the intratumoral cluster of differentiation 8 (CD8+) Thymus (T) cells/regulatory T cell ratio or a 50% decrease in the percentage of intratumoral regulatory T cells as measured using single cell transcriptomics and/or flow cytometry.
Measured: At time of surgery (2 weeks after start of parsaclisib)
Secondary outcomes (4)
Minimum dose of parsaclisib needed to decrease peripheral blood regulatory T cells
To determine the minimum dose of parsaclisib, administered once daily for 14 consecutive days, in subjects with triple-negative or HER2 positive breast cancer resulting in either a 50% increase in the peripheral blood CD8+ T cells/regulatory T-cell ratio or a 50% decrease in the percentage of peripheral blood regulatory T cells as measured using single cell transcriptomics and/or flow cytometry.
Measured: At time of surgery (2 weeks after start of parsaclisib)
Changes in regulatory T cell signature
To identify changes in the regulatory T cell signature following treatment with parsaclisib in subjects with triple-negative or HER2-positive breast cancer. A regulatory T-cell gene signature expression score is defined as the average of upper quartile normalized and log2 transformed gene expression values of all genes belonging to that gene signature was calculated for each sample. Gene expression values will be determined via RNA-sequencing. A one-sided paired t-test will be used to test for significant pre-post reductions in signature values in each subject, reflecting a decrease in the abundance of intratumoral regulatory T cells.
Measured: At time of surgery (2 weeks after start of parsaclisib)
Changes in Ki-67 mRNA expression
To identify changes in Ki-67 messenger Ribonucleic acid (mRNA) expression following treatment with parsaclisib in subjects with triple-negative or HER2-positive breast cancer. Ki-67 expression pre versus post treatment will be assessed using the average log2 fold change in gene expression between conditions.
Measured: At time of surgery (2 weeks after start of parsaclisib)
Comparison of reduction in the regulatory T cell signature by dose of parsaclisib
The reduction in the regulatory T cell signature by dose of parsaclisib (10 mg, 3.0 mg or 1.0 mg) will be measured as Pre and post-treatment levels of regulatory T-cell total abundance (cell count) and relative abundance (percentage of all cells), and change in relative abundance (fold change in % abundance post vs pre-treatment)
Measured: At time of surgery (2 weeks after start of parsaclisib)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Oct 2019
- Study start1 Jun 2020 (estimated)
- Primary completion7 Sep 2020
- Study completion7 Sep 2020
Why it stopped: Funding withdrawn from funding source.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by UNC Lineberger Comprehensive Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- Incyte Corporation
- Responsible party
- Sponsor
- Investigators
- Carey Lisa, MD, Principal investigator, UNC Lineberger Comprehensive Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04142554
- Sponsor's protocol ID
- LCCC1820
- Acronym
- LCCC1820
- Status last verified
- Oct 2020
- First submitted
- 24 Oct 2019
- Last updated
- 3 Nov 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Nov 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Window of Opportunity Study of Parsaclisib in Subjects With Newly Diagnosed Stage I-IIIC Triple-Negative or HER2-Positive Breast Cancer
- ClinicalTrials.gov ID
- NCT04142554
- Acronym / sponsor ID
- LCCC1820 / LCCC1820
- Conditions
- Breast Cancer, Breast Neoplasms, Triple Negative Breast Cancer, HER2-positive Breast Cancer
- Keywords
- breast, triple negative, HER2-positive, parsaclisib
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Funding withdrawn from funding source.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- UNC Lineberger Comprehensive Cancer CenterUniversity, hospital or other
- Collaborators
- Incyte Corporation
- Study start
- 1 Jun 2020 (estimated)
- Primary completion
- 7 Sep 2020 (actual)
- Study completion
- 7 Sep 2020 (actual)
- First posted
- 29 Oct 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this research study is to find the lowest dose of the cancer drug parsaclisib that has an effect on the type of breast cancer a participant has. Researchers are looking at how Parsaclisib affects the immune system. They want to learn whether and how it helps the immune system to find cancer cells to fight them.
Parsaclisib is an oral drug that limits the effects of a protein called phosphatidylinositol 3-kinase δ (PI3K). By limiting P13K, parsaclisib can block certain cells that prevent the immune cells from working. As a result, it may help the body's immune system to fight tumors. Parsaclisib is being studied in several clinical trials to treat different types of cancers. Parsaclisib has not yet been approved by FDA for the treatment of cancer.
Studies have shown that a good way to find out how cancer acts when exposed to anti-cancer drugs is through a pre-operative window study. In this type of study, tissue and blood are collected before treatment. Then subjects receive a study drug for a few weeks before surgery. Blood is drawn during the course of treatment, and leftover tissue is collected during surgery. Comparing the tissue and blood before and after treatment shows the effects the study drug may have had on the tumor.
Research shows that cancers differ when you look at the DNA and RNA (genetic codes) that are inside a cancer cell. DNA and RNA carry genetic information that can determine traits in humans (such as eye color, height, reaction to treatment, etc.), as well as the traits of cancer cells. Depending on the genetic profile (particularly DNA and RNA) of the cancer, it may respond differently to parsaclisib. In this study, the investigators will look at the genetic profile of a participant's tumor by studying tissue and blood samples collected before and after receiving treatment.
Detailed description
Surgery and Treatment:
Subjects must consent to having tissue collected for research purposes during a pre-treatment research biopsy, and scheduled surgery or end of treatment research biopsy prior to study entry. Prior to their scheduled standard of care surgery or research biopsy, subjects (n = 5 per dosing cohort) will be given oral doses of parsaclisib (10, 3.0 or 1.0 mg) once daily over 14 consecutive days. Cohorts will be enrolled sequentially by dose, where the cohort with the highest dose will be enrolled first and then the next cohort with the next highest dose will be enrolled after the enrollment of the prior cohort completes.
At each dose level it will be determined whether either a 50% increase in the intratumoral CD8+ T cells/regulatory T- cell ratio or a 50% decrease in the intratumoral percentage of regulatory T cells is observed in at least 3 subjects out of 5 at that dose level. If this criterion is met, enrollment in the next highest dose level will commence. This procedure will be repeated until either this criterion is met at the lowest dose level, or when the criterion is not satisfied in a particular dose level. In the latter case, the next highest dose level will be chosen as the "minimum effective dose". In the former case, the lowest dose level will be chosen as the minimum effective dose. The doses being administered are lower than the therapeutic dose levels of parsaclisib (i.e., 20 to 30 mg once daily) recommended for subjects with lymphoma. If the criterion is not met in the first (highest) dose level, then the investigators assume the minimum effective dose is the therapeutic dose of parsaclisib (20 mg once daily) and the study will be terminated.
Blood samples will be collected prior to parsaclisib treatment for research purposes. Subjects will undergo their standard of care surgical procedure or research biopsy within 72 hours (preferably within 24 hours) of completing drug treatment. Tissue and blood samples will be collected for correlative studies during surgery or during a research biopsy procedure. Subjects who have at least 7 days of parsaclisib treatment will be considered evaluable and may have tissue collected even if they have not completed the entire 14 day treatment regimen.
Duration of Follow Up:
Subjects will be followed post-operatively as per routine standard of care. Contraceptive use should continue for 93 days after the last dose of study drug administration. Subjects removed from study treatment for unacceptable adverse events will be followed until resolution or stabilization of the adverse event. Monitoring for AEs should continue for at least 30 days after the last dose of parsaclisib is administered. AEs related to therapy will then be followed until resolution to grade ≤1, or until the condition has stabilized with no further change expected.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Single Arm: Parsaclisib ( Dose De-Escalation ) | Experimental | Drug: ParsaclisibPrior to their scheduled standard of care surgery or research biopsy, subjects (n = 5 per dosing cohort) will be given oral doses of parsaclisib (10, 3.0 or 1.0 mg) once daily over 14 consecutive days. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (22 listed)
- Is able to understand and give written informed consent for removal of at least 2 cores of tissue via a pre-treatment research biopsy. Is able to understand and give written informed consent for either collection of leftover tissue at time of surgery and via an end of treatment (EOT) research biopsy).
- Is ≥ 18 years of age.
- Has histologically confirmed newly diagnosed Stage I-IIIC invasive breast cancer that is triple negative (ER/PR <1%, HER2 negative) or HER2-positive, and meets the criteria listed below:
- Must have sufficient time to receive at least 7 consecutive days of parsaclisib therapy prior to definitive surgery or initiation of chemotherapy..
- Has an ECOG performance status ≤ 1.
Key exclusion criteria (12 listed)
- Prior history of another known malignancy other than breast cancer within the previous 2 years with the exception of adequately treated basal cell carcinoma or cervical intraepithelial neoplasia, cervical carcinoma in situ or melanoma in situ.
- Is pregnant or lactating.
- Has a concomitant medical condition that precludes adequate study treatment compliance or assessment, such as bleeding disorders or any other medical condition that would increase risks of additional core biopsy for biomarkers.
- Use of any potent CYP3A4 inhibitors or inducers (e.g., grapefruit or grapefruit juice) within 14 days or 5 half-lives (whichever is longer) before the first dose of parsaclisib.
- Has allergy to inactive components of the study medication.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ParsaclisibParsaclisib tablets (1.0, 2.5 or 5 mg) are administered orally daily for up to 14 days | Drug | Single Arm: Parsaclisib ( Dose De-Escalation ) |
Primary outcome
Minimum effective dose of parsaclisib
Time frame: At time of surgery (2 weeks after start of parsaclisib)
To determine the minimum dose of parsaclisib, administered once daily for 14 consecutive days, needed in subjects with triple-negative or human epidermal growth factor receptor 2 (HER2) positive breast cancer to result in either a 50% increase in the intratumoral cluster of differentiation 8 (CD8+) Thymus (T) cells/regulatory T cell ratio or a 50% decrease in the percentage of intratumoral regulatory T cells as measured using single cell transcriptomics and/or flow cytometry.
4 secondary outcomes
Minimum dose of parsaclisib needed to decrease peripheral blood regulatory T cells
Time frame: At time of surgery (2 weeks after start of parsaclisib)
Changes in regulatory T cell signature
Time frame: At time of surgery (2 weeks after start of parsaclisib)
Changes in Ki-67 mRNA expression
Time frame: At time of surgery (2 weeks after start of parsaclisib)
Comparison of reduction in the regulatory T cell signature by dose of parsaclisib
Time frame: At time of surgery (2 weeks after start of parsaclisib)
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Nov 2020.
- University of North Carolina Lineberger Comprehensive Cancer Center Clinical TrialsLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Carey Lisa, MD principal investigator
UNC Lineberger Comprehensive Cancer Center
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Parsaclisib in people with Breast Cancer and Breast Neoplasms, run by UNC Lineberger Comprehensive Cancer Center.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 22 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 3 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Minimum effective dose of parsaclisib (time frame: At time of surgery (2 weeks after start of parsaclisib)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2020.